AB0441 IMPACT OF URICEMIA ON PSORIATIC ARTHRITIS, AND ON SAFETY AND CLINICAL RESPONSE TO UPADACITINIB AND ADALIMUMAB: POST-HOC ANALYSIS OF PHASE III STUDIES

Authors:

Abstract
Background: Patients (pts) with Psoriasis (PsO) or Psoriatic Arthritis (PsA) are at increased risk for developing gout; and hyperuricemia (HU) prevalence is higher in PsO/PsA pts than the general population1. The pathogenic role of chronic hyperuricemia in the development and maintenance of PsA is based on basic science, epidemiological, and clinical arguments and hence does not appear fortuitous. These two pathological processes can influence each other. Pts with PsA with HU appeared to be more severe and difficult-to-treat than normo-uricemic ones2. Previous post-hoc analysis showed that the profile of pts with vs without HU was distinct but the efficacy of secukinumab (SEC) or guselkumab (GUS) was comparable in hyper- and normo-uricemic pts.3 Objectives: This post-hoc analysis sought to compare PsA patients with vs without HU and evaluate the safety and efficacy of upadacitinib (UPA), a JAK inhibitor, and adalimumab, a TNF-α inhibitor, through 1 year in pts with or without hyperuricemia. Methods: Adults in SELECT-PsA 1&2 with active PsA despite standard therapies were included. HU was defined as baseline (BL) serum urate levels ≥360 μmol/L. Pts without HU (no HU) but with history of gout or urate-lowering therapies were excluded. Patients’ clinical and demographic characteristics were collected at baseline. Adverse events between baseline and week 56 (W56) were recorded. Treatment-Emergent Adverse Events (TEAE) and efficacy were compared between 1049 patients with or without HU and treatment arms up to W56 in pooled UPA 15 mg QD patients from SELECT-PsA 1 & 2 and adalimumab patients from SELECT-PsA 1. The UPA 30 mg QD arms of the studies were excluded from the efficacy and safety analysis as this dosage is not approved in rheumatology. The evaluation of efficacy included the assessment of American College of Rheumatology responses (ACR20/50/70), the Enthesitis Index of the Spondyloarthritis Research Consortium of Canada (SPARCC), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Psoriasis Area and Severity Index (PASI90), the Psoriatic Arthritis Response Criteria (PsARC), radiographic progression (vdH-mTSS), and quality of life (QoL) over W56. The results of the statistical analysis are presented in descriptive form. Results: 2347 pts were included in SELECT-PsA studies (SELECT-PsA 1: 1705 pts & SELECT-PsA 2: 642 pts). Relative to no HU pts (n=1540), those with HU (n=770) were more likely to be male (66.4% vs 36.1%) with higher BMI (32.3 vs 29.7 kg/m2) and more severe PsO. The two cohorts had generally comparable severity of articular symptoms and patient-reported outcomes (Table 1). Incidence of Treatment-Emergent Adverse Events (AE) were comparable between patients with or without HU (any AE 77.8 vs 77.9%). HU pts developed more often metabolic disorders (such as hypertension or diabetes mellitus) but MACE incidence were similar across HU and non-HU pts (0.3% in HU pts vs 0.9% in non-HU) (Table 2). Clinically meaningful and comparable improvements in all studied outcomes were observed at W56 across HU and non-HU cohorts and ADA and UPA groups. Conclusion: In this pooled analysis of pts with active PsA, HU pts were more likely to be male and have a higher BMI and more severe PsO. The observed differential clinical profile and comorbidities, which confirm previous studies3, underscore the value of assessing serum urate levels in PsA pts. Pts with HU were more prone to develop hypertension or diabetes mellitus. UPA was not associated with an increased risk of TEAE event in the HU cohort. UPA and ADA provided clinically meaningful improvements across key PsA domains through W56, irrespective of HU presence. REFERENCES: [1] Felten et al. Clin Rheumatol. 2020 May;39(5):1405-1413 [2] Widawski et al. Clin Rheumatol. 2022 May;41(5):1421-1429 [3] Felten R. et al. RMD Open. 2023 Nov;9(4):e003428 Acknowledgements: AbbVie funded the studies and participated in the data collection, analysis, interpretation of data, and the review and approval of the publication. All authors had access to relevant data and participated in the review, and approval of this publication. No honoraria or payments were made for authorship. Disclosure of Interests: Renaud Felten AbbVie, Amgen, BMS, GSK, Lilly, Nordic, Novartis, Medac, MSD, Pfizer, Sanofi, UCB, Laura WIDAWSKI: None declared, Lionel SPIELMANN: None declared, Jacques-Eric Gottenberg AbbVie, MSD, Novartis, Lilly, Galapagos, Gilead, Pfizer, UCB, AbbVie, MSD, Novartis, Lilly, Galapagos, Gilead, Pfizer, UCB, Pierre-Marie DURET AbbVie, Novartis, Medac, BMS, Sanofi, Pfizer, Sandra VEGAT AbbVie, Laurent MESSER: None declared.